Intranasal delivery of E-selectin reduces atherosclerosis in ApoE-/- mice

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Li, Xinhui ^a   Johnson, Kory R ^a   Bryant, Mark ^b   Elkahloun, Abdel G ^b,d   Amar, Marcelo ^c   Remaley, Alan T ^c   de Silva, Ranil ^c,e   Hallenbeck, John M ^a   Quandt, Jacqueline A ^a,f  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 10; LIPID; MESSENGER RNA; PROTEIN ANTIBODY; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRIACYLGLYCEROL; INTERCELLULAR ADHESION MOLECULE 1; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; CELL INFILTRATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE MARKER; FEMALE; GENE EXPRESSION PROFILING; IMMUNOLOGICAL TOLERANCE; LIPID DIET; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; ATHEROSCLEROSIS; BLOOD; DRUG EFFECT; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ANIMALIA; MUS; RATTUS;

ADMINISTRATION, INTRANASAL; ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; E-SELECTIN; FEMALE; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-10; MICE; MICE, MUTANT STRAINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79959315372     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020620     Document Type: Article

References (62)

1. World Health Organization (WHO) (2004) Atlas of Heart Disease and Stroke.
2. Donnan GA, Fisher M, Macleod M, Davis SM, (2008) Stroke. Lancet 371: 1612-1623.
3. Hansson GK, (2009) Atherosclerosis-an immune disease: The Anitschkov Lecture 2007. Atherosclerosis 202: 2-10.
4. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
5. Hansson GK, Libby P, (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519.
6. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P, (2000) Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 97: 7458-7463.
7. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, et al. (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2: 275-281.
8. Sakaguchi S, Yamaguchi T, Nomura T, Ono M, (2008) Regulatory T cells and immune tolerance. Cell 133: 775-787.
9. Shevach EM, (2006) From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25: 195-201.
10. Faria AM, Weiner HL, (1999) Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 73: 153-264.
11. Maron R, Sukhova G, Faria AM, Hoffmann E, Mach F, et al. (2002) Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106: 1708-1715.
12. George J, Yacov N, Breitbart E, Bangio L, Shaish A, et al. (2004) Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I. Cardiovasc Res 62: 603-609.
13. van Puijvelde GH, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJ, et al. (2006) Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114: 1968-1976.
14. Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, et al. (2010) Intranasal Immunization With an Apolipoprotein B-100 Fusion Protein Induces Antigen-Specific Regulatory T Cells and Reduces Atherosclerosis. Arterioscler Thromb Vasc Biol.
15. Mayer L, Shao L, (2004) Therapeutic potential of oral tolerance. Nat Rev Immunol 4: 407-419.
16. Broere F, Wieten L, Klein Koerkamp EI, van Roon JA, Guichelaar T, et al. (2008) Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. J Immunol 181: 899-906.
17. Kansas GS, (1996) Selectins and their ligands: current concepts and controversies. Blood 88: 3259-3287.
18. Polin RS, Bavbek M, Shaffrey ME, Billups K, Bogaev CA, et al. (1998) Detection of soluble E-selectin, ICAM-1, VCAM-1, and L-selectin in the cerebrospinal fluid of patients after subarachnoid hemorrhage. J Neurosurg 89: 559-567.
19. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, et al. (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96: 4219-4225.
20. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, (1995) Soluble E-selectin in the serum and cerebrospinal fluid of patients with multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy. Neurology 45: 1914-1918.
21. Malatino LS, Stancanelli B, Cataliotti A, Bellanuova I, Fatuzzo P, et al. (2007) Circulating E-selectin as a risk marker in patients with end-stage renal disease. J Intern Med 262: 479-487.
22. Kozuka K, Kohriyama T, Nomura E, Ikeda J, Kajikawa H, et al. (2002) Endothelial markers and adhesion molecules in acute ischemic stroke-sequential change and differences in stroke subtype. Atherosclerosis 161: 161-168.
23. Takeda H, Spatz M, Ruetzler C, McCarron R, Becker K, et al. (2002) Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke 33: 2156-2163.
24. Chen Y, Ruetzler C, Pandipati S, Spatz M, McCarron RM, et al. (2003) Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A 100: 15107-15112.
25. Ishibashi S, Maric D, Mou Y, Ohtani R, Ruetzler C, et al. (2009) Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. J Cereb Blood Flow Metab 29: 606-620.
26. Wakita H, Ruetzler C, Illoh KO, Chen Y, Takanohashi A, et al. (2008) Mucosal tolerization to E-selectin protects against memory dysfunction and white matter damage in a vascular cognitive impairment model. J Cereb Blood Flow Metab 28: 341-353.
27. Illoh K, Campbell C, Illoh O, Diehl J, Cherry J, et al. (2006) Mucosal tolerance to E-selectin and response to systemic inflammation. J Cereb Blood Flow Metab 26: 1538-1550.
28. Nakayama T, Illoh K, Ruetzler C, Auh S, Sokoloff L, et al. (2007) Intranasal administration of E-selectin to induce immunological tolerization can suppress subarachnoid hemorrhage-induced vasospasm implicating immune and inflammatory mechanisms in its genesis. Brain Res 1132: 177-184.
29. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, et al. (2004) Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10: 416-421.
30. Damas JK, Smith C, Oie E, Fevang B, Halvorsen B, et al. (2007) Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol 27: 614-620.
31. Oksjoki R, Kovanen PT, Meri S, Pentikainen MO, (2007) Function and regulation of the complement system in cardiovascular diseases. Frontiers in Bioscience 12: 4696-4708.
32. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM, (2004) The role of the complement system in ischemia-reperfusion injury. Shock 21: 401-409.
33. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C, (1990) A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project-1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 53: 16-22.
34. Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, et al. (2007) Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 316: 285-288.
35. Yoshioka T, Okada T, Maeda Y, Ikeda U, Shimpo M, et al. (2004) Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Ther 11: 1772-1779.
36. Weiner HL, (2004) Current issues in the treatment of human diseases by mucosal tolerance. Ann N Y Acad Sci 1029: 211-224.
37. Akbari O, Stock P, DeKruyff RH, Umetsu DT, (2003) Mucosal tolerance and immunity: regulating the development of allergic disease and asthma. Int Arch Allergy Immunol 130: 108-118.
38. Samsom JN, (2004) Regulation of antigen-specific regulatory T-cell induction via nasal and oral mucosa. Crit Rev Immunol 24: 157-177.
39. Potteaux S, Esposito B, van Oostrom O, Brun V, Ardouin P, et al. (2004) Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 24: 1474-1478.
40. Liu Y, Li D, Chen J, Xie J, Bandyopadhyay S, et al. (2006) Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 188: 19-27.
41. Han X, Kitamoto S, Lian Q, Boisvert WA, (2009) Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages. J Biol Chem 284: 32950-32958.
42. Smith KA, (1988) Interleukin-2: inception, impact, and implications. Science 240: 1169-1176.
43. Lan RY, Selmi C, Gershwin ME, (2008) The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 31: 7-12.
44. Burchill MA, Yang J, Vang KB, Farrar MA, (2007) Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett 114: 1-8.
45. Cao W, Chen Y, Alkan S, Subramaniam A, Long F, et al. (2005) Human T helper (Th) cell lineage commitment is not directly linked to the secretion of IFN-gamma or IL-4: characterization of Th cells isolated by FACS based on IFN-gamma and IL-4 secretion. Eur J Immunol 35: 2709-2717.
46. Yoneyama H, Matsuno K, Zhang YY, Murai M, Itakura M, et al. (2001) Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease. Journal of Experimental Medicine 193: 35-49.
47. Hjelmstrom P, Fjell J, Nakagawa T, Sacca R, Cuff CA, et al. (2000) Lymphoid tissue homing chemokines are expressed in chronic inflammation. American Journal of Pathology 156: 1133-1138.
48. Damas JK, Smith C, Oie E, Fevang B, Halvorsen B, et al. (2007) Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis- Possible pathogenic role in plaque destabilization. Arteriosclerosis Thrombosis and Vascular Biology 27: 614-620.
49. Chen SC, Leach MW, Chen YY, Cai XY, Sullivan L, et al. (2002) Central nervous system inflammation and neurological disease in transgenic mice expressing the CC chemokine CCL21 in oligodendrocytes. Journal of Immunology 168: 1009-1017.
50. Biber K, Sauter A, Brouwer N, Copray SCVM, Boddeke HWGM, (2001) Ischemia-induced neuronal expression of the microglia attracting chemokine secondary lymphoid-tissue chemokine (SLC). Glia 34: 121-133.
51. Engelhardt B, (2006) Molecular mechanisms involved in T cell migration across the blood-brain barrier. Journal of Neural Transmission 113: 477-485.
52. Huehn J, Hamann A, (2005) Homing to suppress: address codes for Treg migration. Trends Immunol 26: 632-636.
53. Moustakas A, Heldin CH, (2009) The regulation of TGFbeta signal transduction. Development 136: 3699-3714.
54. Feinberg MW, Watanabe M, Lebedeva MA, Depina AS, Hanai J, et al. (2004) Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem 279: 16388-16393.
55. Clark-Greuel JN, Connolly JM, Sorichillo E, Narula NR, Rapoport HS, et al. (2007) Transforming growth factor-beta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. Ann Thorac Surg 83: 946-953.
56. Xu S, Liu AC, Gotlieb AI, (2009) Common pathogenic features of atherosclerosis and calcific aortic stenosis: role of transforming growth factor-beta. Cardiovasc Pathol.
57. Wang XL, Liu SX, Wilcken DE, (1997) Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res 34: 404-410.
58. Bogavac-Stanojevic N, Djurovic S, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Kalimanovska-Ostric D, (2003) Circulating transforming growth factor-beta1, lipoprotein(a) and cellular adhesion molecules in angiographically assessed coronary artery disease. Clin Chem Lab Med 41: 893-898.
59. Oh IY, Yoon CH, Hur J, Kim JH, Kim TY, et al. (2007) Involvement of E-selectin in recruitment of endothelial progenitor cells and angiogenesis in ischemic muscle. Blood 110: 3891-3899.
60. Peranteau WH, Zhang L, Muvarak N, Badillo AT, Radu A, et al. (2008) IL-10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation. J Invest Dermatol 128: 1852-1860.
61. Shechter R, London A, Varol C, Raposo C, Cusimano M, et al. (2009) Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 6: e1000113.
62. Frangogiannis NG, (2006) Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 13: 1877-1893.